menu
    • menu
    [{"orgOrder":0,"company":"Genuv","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"SNR1611","moa":"MEK1\/2","graph1":"Neurology","graph2":"Preclinical","graph3":"Genuv","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genuv \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Genuv \/ Not Applicable"},{"orgOrder":0,"company":"Genuv","sponsor":"Nanocarry Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"GNUV201","moa":"PD-1","graph1":"Oncology","graph2":"Preclinical","graph3":"Genuv","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Genuv \/ Nanocarry Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Genuv \/ Nanocarry Therapeutics"},{"orgOrder":0,"company":"Genuv","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Trametinib","moa":"MEK 1\/2","graph1":"Neurology","graph2":"IND Enabling","graph3":"Genuv","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genuv \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Genuv \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Genuv

    Menu

    Genuv

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Genuv

                            South Korea arrow
                            BOS Manchester
                            Not Confirmed

                            Genuv

                            South Korea arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trametinib

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Publication in Nature Molecular Psychiatry Supports Genuv’s Alternate Theory for Treatment of Alzheimer’s ...

                            Details : SNR1611 (trametinib) was the first drug candidate identified at Genuv with the ATRIVIEW® platform. It showed the most potent neurogenerative and neuroprotective effects in a library of FDA-approved drug compounds.

                            Brand Name : SNR1611

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 18, 2022

                            Lead Product(s) : Trametinib

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Genuv

                            South Korea arrow
                            BOS Manchester
                            Not Confirmed

                            Genuv

                            South Korea arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GNUV201

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Nanocarry Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Genuv Teams With Nanocarry Therapeutics to Develop Novel anti-PD-1 mAb Treatments That Can Cross the Blood-Bra...

                            Details : GNUV201 is an experimental, novel anti-PD-1 monoclonal antibody developed with Genuv’s proprietary antibody development platform Shine Mouse®. GNUV201 exhibits strong cross-reactivity to both human and mouse PD-1.

                            Brand Name : GNUV201

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 06, 2022

                            Lead Product(s) : GNUV201

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Nanocarry Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Genuv

                            South Korea arrow
                            BOS Manchester
                            Not Confirmed

                            Genuv

                            South Korea arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNR1611

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Genuv Announces Preclinical Data to be Released at Two Medical Conferences in June

                            Details : SNR1611 is drug candidate that has been repurposed for neurodegenerative disease from a previously FDA-approved anti-cancer drug, has already confirmed SNR1611’s effect on neuron regeneration and functional recovery through preclinical research.

                            Brand Name : SNR1611

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 23, 2022

                            Lead Product(s) : SNR1611

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth